Trial Profile
A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf 06260414 In Healthy Western And Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs PF 626414 (Primary)
- Indications Cachexia
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 13 Apr 2016 Results published in the Clinical Therapeutics
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 16 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.